Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease

This publication has 35 references indexed in Scilit:

• Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki Disease
  The Journal of Pediatrics, 2008
• Resistance to Intravenous Immunoglobulin in Children with Kawasaki Disease
  The Journal of Pediatrics, 2008
• Less Subclinical Atherosclerosis in Japanese Men in Japan than in White Men in the United States in the Post-World War II Birth Cohort
  American Journal of Epidemiology, 2007
• A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: Clinical course and coronary artery outcome
  The Journal of Pediatrics, 2006
• Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies
  JAMA, 2006
• Review of Trials in Chronic Heart Failure Showing Broad-Spectrum Anti-Inflammatory Approaches
  The American Journal of Cardiology, 2005
• Population Pharmacokinetic Analysis and Simulation of the Time‐Concentration Profile of Etanercept in Pediatric Patients With Juvenile Rheumatoid Arthritis
  The Journal of Clinical Pharmacology, 2005
• Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure
  Circulation, 2003
• Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease
  The Journal of Pediatrics, 1994
• Serum-soluble interleukin-2 receptor levels in Kawasaki disease
  The Journal of Pediatrics, 1990